Biopharma <\/strong>buys<\/h2>\nThis feels like a good time to buy biopharma as a contrarian investment, particularly with the tailwind of boomer aging driving demand over the next 10-20 years.\u00a0<\/p>\n
Healthcare plays look particularly cheap right now because investors despise biopharma stocks. \u201cSector sentiment feels pretty close to an all-time low,\u201d Baird biotech analyst Brian Skorney reports.\u00a0<\/p>\n
Investors are worried about three factors, says Morningstar analyst Karen Andersen: Inflation Reduction Act (IRA) policies giving the federal government more control over drug prices; patent losses, and aggressive Federal Trade Commission challenges to proposed mergers. She discounts these risks.\u00a0<\/p>\n
\u201cThe biopharma-related policies in the IRA are manageable, and that innovation will offset the patent losses,\u201d Andersen says. \u201cThe market is underappreciating the significance of innovation in the biopharma industry.\u201d<\/p>\n
Here are three timely health care stocks that reflect this theme \u2014 two that company insiders favor and one from Morningstar Direct, which does solid stock research.<\/p>\n
1.<\/strong> AstraZeneca (AZN)<\/strong><\/p>\nThis drug maker is particularly strong in therapies for ailments that affect the elderly \u2014 including cancer, cardiovascular disease and diabetes. AstraZeneca\u2019s
\n AZN,
\n -2.40%<\/bg-quote>
\n biggest business is cancer therapies. The company derives about 39% of its revenue from this area. It recently launched the cancer drugs Tagrisso, Imfinzi, Lynparza, and Calquence for lung cancer, breast cancer and lymphoma, respectively. \u201cThese drugs carry strong pricing power to support higher margin sales,\u201d Morningstar analyst Damien Conover says.<\/p>\nAstraZeneca has a lot more products on the way, because it spends so much on research \u2014 well-above the industry average. AstraZeneca\u2019s research emphasizes the development of therapies for cancer, heart failure, COPD, kidney disease and respiratory illness, all of which affect the elderly more. <\/p>\n
Conover says AstraZeneca\u2019s pipeline is one of the strongest in the drug group. It has more than 120 Phase II and Phase III trials in progress, including on several therapies with blockbuster potential. Conover adds that many of these drugs will command high prices, so margins will improve. He projects 8% annual sales growth over the next five years.\u00a0<\/p>\n
Another bullish factor: The company gets just 41% of its revenue from U.S. sales. This limits the potential impact of government price controls to some degree. Conover also assigns AstaZeneca a wide moat based on its patents and distribution network.<\/p>\n
2. Zimmer Biomet (ZBH)<\/strong><\/p>\nIf you know anyone who has gotten a hip or knee replacement, the chances are good they are now walking with help from a Zimmer Biomet
\n ZBH,
\n +0.07%<\/bg-quote>
\n product. The company makes orthopedic reconstructive products, mainly for knee and hip replacement. It also sells a suite of robotic products that help with surgery, such as the recently-introduced ROSA Robot.\u00a0<\/p>\nIn the most recent quarter, the company posted decent 6% sales growth and boosted guidance to 6.5%-7% sales growth this year, up from prior guidance of 5%-6%. The upper end of EPS guidance went to $7.57 from $7.50.\u00a0<\/p>\n
Nevertheless, the stock has fallen sharply to the low $100 range from around $145 last summer. What might turn the stock around? The company is bullish on sales growth from two new product lines \u2014 the ROSA Robot surgery robot, and Persona OsseoTi Keel Tibia, a new cementless tibia used in total knee replacement.\u00a0<\/p>\n
\u201cIt\u2019s early innings, frankly, both for ROSA as well as cementless,\u201d CEO Ivan Tornos said on the latest earnings call. The Persona OsseoTi Keel Tibia launch has been hit by supply issues which will be resolved early in the first quarter of 2024, he says.\u00a0<\/p>\n
And of course, rising boomer demand for new knees and hips will drive growth.\u00a0<\/p>\n
In the current sell off, a cluster of Zimmer Biomet insiders purchased about $700,000 worth of stock in the $112-$120 range. Cluster-buys are a positive signal in insider analysis. Morningstar has a five-star rating (out of five) on Zimmer, and it assigns the company a wide economic moat, mainly due to switching costs for surgeons. The learning curve to become proficient in a new set of instruments used in replacement surgery is steep.\u00a0<\/p>\n
3. STAAR Surgical (STAA)<\/strong><\/p>\nThis company sells implantable lenses used in normal vision correction and cataract surgery. The cataract correction market is growing because of the aging of the boomer population. Most people develop cataracts by the time they are in their 70s.\u00a0<\/p>\n
Despite the aging of the boomer generation, STAAR Surgical
\n STAA,
\n +0.81%<\/bg-quote>
\n stock has been cut more than half to $39 from $80 back in February. The problem here is the company has an implantable lens technology that is not yet gaining traction in the U.S., despite its popularity in Asia.\u00a0<\/p>\nIt is called EVO ICL. The \u201cICL\u201d in the name stands for implantable Collamer lens. Collamer is the name of the material the company uses. EVO ICL is a super slim lens implanted in the eye. Think of it as a permanent contact lens. The challenge is that EVO ICL competes laser-assisted in-situ keratomileusis (LASIK) surgery. Because it is less invasive and cheaper, LASIK is often the treatment of choice in the U.S.\u00a0<\/p>\n
This is one reason that STAAR Surgical has been guiding down on growth, which has hurt the stock. But the new guidance is not terrible. The company expects to post 20% sales growth this year. \u201cWe believe we will continue to be a high-growth company beyond 2023 in the 15% to 20% range,\u201d CEO Tom Frinzi says.\u00a0<\/p>\n
EVO ICL is popular in other parts of the world, and Frinzi is optimistic that the U.S. will catch up. \u201cWe remain confident this market will achieve the growth levels we have seen in our other target markets.\u201d Steps to help make this happen include new management, attempts to improve relations with eye surgeons, and better use of statistical analysis to identify and target high-volume customers.\u00a0<\/p>\n
The big insider buyer is a beneficial owner (10% owner) called Broadwood Partners. It has a good record here and it is buying in size, or around $7.9 million worth. A director also bought $97,000 worth. The buying happened in the $41 range and the stock is cheaper now.\u00a0<\/p>\n
Michael Brush is a columnist for MarketWatch. At the time of publication, he owned ZBH and STAA. Brush has suggested ZBH and STAA in his stock newsletter,\u00a0Brush Up on Stocks. Follow him on X @mbrushstocks<\/em>.<\/p>\nMore:<\/strong> How to play the coming January bounce-back for 2023\u2019s stock-market losers<\/p>\nAlso read: <\/strong>Among the S&P 500, these 20 companies have made the best use of investors\u2019 money<\/p>\n<\/p><\/div>\nRead the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Baby boomers: Love \u2018em or hate \u2018em, the juggernaut generation changes every aspect of life it steamrolls through. Now it\u2019s doing the…<\/p>\n","protected":false},"author":1,"featured_media":6755,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":{"0":"post-6754","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investment"},"yoast_head":"\n
Opinion: These 3 healthcare stocks should come to life as boomers live their golden years | inFundPros<\/title>\n<meta name=\"description\" content=\"Baby boomers: Love \u2018em or hate \u2018em, the juggernaut generation changes every aspect of life it steamrolls through. Now it\u2019s doing the same to healthcare.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/infundpros.com\/?p=6754\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opinion: These 3 healthcare stocks should come to life as boomers live their golden years | inFundPros\" \/>\n<meta property=\"og:description\" content=\"Baby boomers: Love \u2018em or hate \u2018em, the juggernaut generation changes every aspect of life it steamrolls through. Now it\u2019s doing the same to healthcare.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/infundpros.com\/?p=6754\" \/>\n<meta property=\"og:site_name\" content=\"inFundPros\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-29T15:39:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-29T15:39:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/1698593945_social.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1279\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Press Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Press Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/infundpros.com\/?p=6754#article\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/?p=6754\"},\"author\":{\"name\":\"Press Room\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\"},\"headline\":\"Opinion: These 3 healthcare stocks should come to life as boomers live their golden years\",\"datePublished\":\"2023-10-29T15:39:05+00:00\",\"dateModified\":\"2023-10-29T15:39:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/infundpros.com\/?p=6754\"},\"wordCount\":1177,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"articleSection\":[\"Investment\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/infundpros.com\/?p=6754#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/infundpros.com\/?p=6754\",\"url\":\"https:\/\/infundpros.com\/?p=6754\",\"name\":\"Opinion: These 3 healthcare stocks should come to life as boomers live their golden years | inFundPros\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/#website\"},\"datePublished\":\"2023-10-29T15:39:05+00:00\",\"dateModified\":\"2023-10-29T15:39:06+00:00\",\"description\":\"Baby boomers: Love \u2018em or hate \u2018em, the juggernaut generation changes every aspect of life it steamrolls through. Now it\u2019s doing the same to healthcare.\",\"breadcrumb\":{\"@id\":\"https:\/\/infundpros.com\/?p=6754#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/infundpros.com\/?p=6754\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/infundpros.com\/?p=6754#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/infundpros.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Opinion: These 3 healthcare stocks should come to life as boomers live their golden years\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/infundpros.com\/#website\",\"url\":\"https:\/\/infundpros.com\/\",\"name\":\"Fintech Advance\",\"description\":\"Latest Finance and Tech News and Updates\",\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/infundpros.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/infundpros.com\/#organization\",\"name\":\"Fintech Advance\",\"url\":\"https:\/\/infundpros.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"width\":409,\"height\":70,\"caption\":\"Fintech Advance\"},\"image\":{\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\",\"name\":\"Press Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"caption\":\"Press Room\"},\"sameAs\":[\"https:\/\/infundpros.com\"],\"url\":\"https:\/\/infundpros.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opinion: These 3 healthcare stocks should come to life as boomers live their golden years | inFundPros","description":"Baby boomers: Love \u2018em or hate \u2018em, the juggernaut generation changes every aspect of life it steamrolls through. Now it\u2019s doing the same to healthcare.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/infundpros.com\/?p=6754","og_locale":"en_US","og_type":"article","og_title":"Opinion: These 3 healthcare stocks should come to life as boomers live their golden years | inFundPros","og_description":"Baby boomers: Love \u2018em or hate \u2018em, the juggernaut generation changes every aspect of life it steamrolls through. Now it\u2019s doing the same to healthcare.","og_url":"https:\/\/infundpros.com\/?p=6754","og_site_name":"inFundPros","article_published_time":"2023-10-29T15:39:05+00:00","article_modified_time":"2023-10-29T15:39:06+00:00","og_image":[{"width":1279,"height":640,"url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/1698593945_social.jpeg","type":"image\/jpeg"}],"author":"Press Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Press Room","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/infundpros.com\/?p=6754#article","isPartOf":{"@id":"https:\/\/infundpros.com\/?p=6754"},"author":{"name":"Press Room","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff"},"headline":"Opinion: These 3 healthcare stocks should come to life as boomers live their golden years","datePublished":"2023-10-29T15:39:05+00:00","dateModified":"2023-10-29T15:39:06+00:00","mainEntityOfPage":{"@id":"https:\/\/infundpros.com\/?p=6754"},"wordCount":1177,"commentCount":0,"publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"articleSection":["Investment"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/infundpros.com\/?p=6754#respond"]}]},{"@type":"WebPage","@id":"https:\/\/infundpros.com\/?p=6754","url":"https:\/\/infundpros.com\/?p=6754","name":"Opinion: These 3 healthcare stocks should come to life as boomers live their golden years | inFundPros","isPartOf":{"@id":"https:\/\/infundpros.com\/#website"},"datePublished":"2023-10-29T15:39:05+00:00","dateModified":"2023-10-29T15:39:06+00:00","description":"Baby boomers: Love \u2018em or hate \u2018em, the juggernaut generation changes every aspect of life it steamrolls through. Now it\u2019s doing the same to healthcare.","breadcrumb":{"@id":"https:\/\/infundpros.com\/?p=6754#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/infundpros.com\/?p=6754"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/infundpros.com\/?p=6754#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/infundpros.com\/"},{"@type":"ListItem","position":2,"name":"Opinion: These 3 healthcare stocks should come to life as boomers live their golden years"}]},{"@type":"WebSite","@id":"https:\/\/infundpros.com\/#website","url":"https:\/\/infundpros.com\/","name":"Fintech Advance","description":"Latest Finance and Tech News and Updates","publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/infundpros.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/infundpros.com\/#organization","name":"Fintech Advance","url":"https:\/\/infundpros.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","width":409,"height":70,"caption":"Fintech Advance"},"image":{"@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff","name":"Press Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/person\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","caption":"Press Room"},"sameAs":["https:\/\/infundpros.com"],"url":"https:\/\/infundpros.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/6754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6754"}],"version-history":[{"count":1,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/6754\/revisions"}],"predecessor-version":[{"id":6756,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/6754\/revisions\/6756"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/media\/6755"}],"wp:attachment":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}